GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Momenta Pharmaceuticals Inc (NAS:MNTA) » Definitions » Cyclically Adjusted PB Ratio

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Cyclically Adjusted PB Ratio : (As of May. 05, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Momenta Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Momenta Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Momenta Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Momenta Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Momenta Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Momenta Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Momenta Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Momenta Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Momenta Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Momenta Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Momenta Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2020 is calculated as:

For example, Momenta Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2020 was:

Adj_Book=Book Value per Share/CPI of Jun. 2020 (Change)*Current CPI (Jun. 2020)
=3.333/108.7673*108.7673
=3.333

Current CPI (Jun. 2020) = 108.7673.

Momenta Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201009 2.428 92.162 2.865
201012 4.143 92.474 4.873
201103 5.227 94.283 6.030
201106 6.573 95.235 7.507
201109 7.821 95.727 8.886
201112 7.860 95.213 8.979
201203 7.810 96.783 8.777
201206 7.674 96.819 8.621
201209 7.248 97.633 8.075
201212 6.971 96.871 7.827
201303 6.549 98.209 7.253
201306 6.058 98.518 6.688
201309 5.661 98.790 6.233
201312 5.154 98.326 5.701
201403 4.697 99.695 5.124
201406 4.272 100.560 4.621
201409 3.793 100.428 4.108
201412 3.788 99.070 4.159
201503 3.771 99.621 4.117
201506 6.062 100.684 6.549
201509 5.710 100.392 6.186
201512 5.356 99.792 5.838
201603 5.066 100.470 5.484
201606 4.734 101.688 5.064
201609 4.587 101.861 4.898
201612 5.233 101.863 5.588
201703 5.084 102.862 5.376
201706 5.076 103.349 5.342
201709 4.719 104.136 4.929
201712 4.900 104.011 5.124
201803 4.337 105.290 4.480
201806 3.614 106.317 3.697
201809 3.174 106.507 3.241
201812 4.682 105.998 4.804
201903 4.271 107.251 4.331
201906 3.169 108.070 3.189
201909 2.793 108.329 2.804
201912 3.902 108.420 3.914
202003 3.641 108.902 3.637
202006 3.333 108.767 3.333

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Momenta Pharmaceuticals  (NAS:MNTA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Momenta Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Momenta Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Binney Street, Cambridge, MA, USA, 02142
Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.
Executives
Bruce Downey director
Alejandra Carvajal officer: Chief Legal Officer C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Jose-carlos Gutierrez-ramos director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Georges Gemayel director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Elizabeth Stoner director C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142
Santiago Arroyo officer: SVP, Chief Medical Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Young Kwon officer: Chief Financial & Bus. Officer C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Ian Fier officer: Chief Mfg and Program Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Jo Ann Beltramello officer: Chief HR and Inf. Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Anthony M. Manning officer: Chief Scientific Officer C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Agnieszka Cieplinska officer: Chief Accounting Officer (PAO) C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Craig A Wheeler director, officer: President & CEO